Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations
Viruses · 2025
DOI: 10.3390/v17081062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Mengqi Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102,…. Hauptthemen laut MEDLINE: Viral Matrix Proteins, SARS-CoV-2, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Recombinant vesicular stomatitis virus (rVSV) is a promising viral vaccine vector for addressing the COVID-19 pandemic. Inducing mucosal immunity via the intranasal route is an ideal strategy for rVSV-based vaccines, but it requires extremely stringent safety standards. In this study, we constructed two rVSV variants with amino acid mutations in their M protein: rVSV-M2 with M33A/M51R mutations and rVSV-M4 with M33A/M51R/V221F/S226R mutations, and developed COVID-19 vaccines based on these attenuated vectors. By comparing viral replication capacity, intranasal immunization, intracranial injection, and blood cell counts, we demonstrated that the M protein mutation variants exhibit significant attenuation effects both in vitro and in vivo. Moreover, preliminary investigations into the mechanisms of virus attenuation revealed that these attenuated viruses can induce a stronger type I interferon response while reducing inflammation compared to the wild-type rVSV. We developed three candidate vaccines against SARS-CoV-2 using the wildtype VSV backbone with either wild-type M (rVSV-JN.1) and two M mutant variants (rVSV-M2-JN.1 and rVSV-M4-JN.1). Our results confirmed that rVSV-M2-JN.1 and rVSV-M4-JN.1 retain strong immunogenicity while enhancing safety in hamsters. In summary, the rVSV variants with M protein mutations represent promising candidate vectors for mucosal vaccines and warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
- National Innovation Platform for Industry-Education Integration in Vaccine Research, NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, Xiamen University, Xiamen 361102, China.
ORCID-Profile: Mengqi Chang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Beijing Natural Science Foundation
Zitieren
APA
Chang, M., Huang, H., Yue, M., Jiang, Y., Yan, S., Chen, Y., Wu, W., Gao, Y., Fang, M., Yuan, Q., Xiong, H., & Zhang, T. (2025). Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations. Viruses. https://doi.org/10.3390/v17081062
Vancouver
Chang M, Huang H, Yue M, Jiang Y, Yan S, Chen Y, et al. Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations. Viruses. 2025. doi:10.3390/v17081062
BibTeX
@article{Chang2025,
author = {Chang, Mengqi and Huang, Hui and Yue, Mingxi and Jiang, Yuetong and Yan, Siping and Chen, Yiyi and Wu, Wenrong and Gao, Yibing and Fang, Mujin and Yuan, Quan and Xiong, Hualong and Zhang, Tianying},
title = {Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17081062}
}
EUVIMED